Emmaus Life Sciences AI Stock Analysis
Want to see EMMA full AI Analyst Report?
Emmaus Life Sciences (EMMA) AI Stock Analysis
Emmaus Life Sciences
(Other OTC:EMMA)
The score is primarily held down by weak financial fundamentals—especially the stressed balance sheet with negative equity and ongoing net losses—despite strong gross margins and a recent improvement to positive free cash flow. Technicals add further pressure as the stock trades below key moving averages with negative MACD and oversold momentum. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is available.
Emmaus Life Sciences (EMMA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 151.72K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -0.98
- Revenue Growth
- 10.98%
- EPS Growth
- -72.08%
- Country
- US
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Emmaus Life Sciences Business Overview & Revenue Model
Company Description
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and...
How the Company Makes Money
Emmaus Life Sciences has historically generated revenue primarily from product sales of Endari (L-glutamine oral powder) for sickle cell disease. Revenue is generally recognized when product is sold and delivered to customers (e.g., wholesalers/speci...
Emmaus Life Sciences Financial Statement Overview
Summary
Income statement shows strong revenue growth (~29% TTM) and very high gross margins (~93–96%), but profitability remains deeply negative (TTM net margin around -39%) and operating results have been inconsistent. Balance sheet is the major constraint with persistently negative equity (worsening to about -$66M) and meaningful debt (~$30–33M), increasing financial flexibility and dilution/refinancing risk. Cash flow improved to positive operating and free cash flow (~$4M TTM), but durability is not yet proven given prior volatility.
Income Statement
38NegativeBalance Sheet
22NegativeCash Flow
46Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.53M | 12.45M | 16.65M | 29.60M | 18.39M | 20.61M |
| Gross Profit | 14.54M | 11.60M | 15.45M | 28.25M | 15.80M | 17.30M |
| EBITDA | 3.40M | -310.00K | -910.00K | 3.62M | -5.50M | -12.76M |
| Net Income | -6.02M | -7.49M | -6.45M | -3.73M | -10.63M | -15.95M |
Balance Sheet | ||||||
| Total Assets | 16.37M | 21.44M | 23.60M | 35.18M | 48.23M | 56.73M |
| Cash, Cash Equivalents and Short-Term Investments | 2.81M | 2.13M | 1.39M | 2.55M | 2.02M | 2.28M |
| Total Debt | 30.52M | 32.56M | 32.96M | 32.65M | 30.82M | 29.91M |
| Total Liabilities | 82.55M | 85.04M | 80.08M | 82.94M | 82.32M | 78.18M |
| Stockholders Equity | -66.18M | -63.61M | -56.48M | -47.76M | -34.09M | -21.45M |
Cash Flow | ||||||
| Free Cash Flow | 3.96M | -12.00K | -2.30M | -1.52M | -5.10M | -1.33M |
| Operating Cash Flow | 3.97M | -11.00K | -2.29M | -1.50M | -5.07M | -1.25M |
| Investing Cash Flow | 1.58M | 2.17M | 2.50M | -432.00K | -2.39M | -6.38M |
| Financing Cash Flow | -3.60M | -1.43M | -1.35M | 2.48M | 7.23M | 7.41M |
Emmaus Life Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 28.36 is Positive, neither overbought nor oversold. The STOCH value of 18.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EMMA.
Emmaus Life Sciences Risk Analysis
Emmaus Life Sciences disclosed 32 risk factors in its most recent earnings report. Emmaus Life Sciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksEmmaus Life Sciences Peers Comparison
Overall Rating
SCNI45Neutral
DRMA40Underperform- EMMA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SCNI | 45Neutral | $688.79K | 0.00 | -23.86% | ― | 143.06% | 94.98% |
| DRMA | 40Underperform | $3.53M | -0.20 | -189.68% | ― | ― | 83.79% |
| EMMA | 39Underperform | $1.54M | -0.16 | 9.37% | ― | 10.98% | -72.08% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EMMA | Emmaus Life Sciences Inc | 0.01 | 0.00 | 50.00% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.44 | -9.18 | -95.41% | |
| ADTX | Aditxt, Inc. | 0.04 | -915.80 | -100.00% | |
| DRMA | Dermata Therapeutics, Inc. | 0.66 | -2.18 | -76.76% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.06 | -86.30% | |
| CDT | Cdt Equity Inc. | 0.44 | -273949.59 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026